Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis by Cortazar, Patricia et al.
Articles
164 www.thelancet.com   Vol 384   July 12, 2014
Pathological complete response and long-term clinical 
beneﬁ t in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, 
Luca Gianni, Pinuccia Valagussa, Sandra M Swain, Tatiana Prowell, Sibylle Loibl, D Lawrence Wickerham, Jan Bogaerts, Jose Baselga, 
Charles Perou, Gideon Blumenthal, Jens Blohmer, Eleftherios P Mamounas, Jonas Bergh, Vladimir Semiglazov, Robert Justice, Holger Eidtmann, 
Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E Geyer Jr, 
Richard Pazdur, Nina Ditsch, Priya Rastogi, Wolfgang Eiermann, Gunter von Minckwitz
Summary
Background Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term 
clinical beneﬁ t, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key 
objectives: to establish the association between pathological complete response and EFS and OS, to establish the 
deﬁ nition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer 
subtypes in which pathological complete response is best correlated with long-term outcome, and to assess whether an 
increase in frequency of pathological complete response between treatment groups predicts improved EFS and OS.
Methods We searched PubMed, Embase, and Medline for clinical trials of neoadjuvant treatment of breast cancer. To 
be eligible, studies had to meet three inclusion criteria: include at least 200 patients with primary breast cancer 
treated with preoperative chemotherapy followed by surgery; have available data for pathological complete response, 
EFS, and OS; and have a median follow-up of at least 3 years. We compared the three most commonly used deﬁ nitions 
of pathological complete response—ypT0 ypN0, ypT0/is ypN0, and ypT0/is—for their association with EFS and OS 
in a responder analysis. We assessed the association between pathological complete response and EFS and OS in 
various subgroups. Finally, we did a trial-level analysis to assess whether pathological complete response could be 
used as a surrogate endpoint for EFS or OS.
Findings We obtained data from 12 identiﬁ ed international trials and 11 955 patients were included in our responder 
analysis. Eradication of tumour from both breast and lymph nodes (ypT0 ypN0 or ypT0/is ypN0) was better associated 
with improved EFS (ypT0 ypN0: hazard ratio [HR] 0·44, 95% CI 0·39–0·51; ypT0/is ypN0: 0·48, 0·43–0·54) and OS 
(0·36, 0·30–0·44; 0·36, 0·31–0·42) than was tumour eradication from the breast alone (ypT0/is; EFS: HR 0·60, 95% CI 
0·55–0·66; OS 0·51, 0·45–0·58). We used the ypT0/is ypN0 deﬁ nition for all subsequent analyses. The association 
between pathological complete response and long-term outcomes was strongest in patients with triple-negative breast 
cancer (EFS: HR 0·24, 95% CI 0·18–0·33; OS: 0·16, 0·11–0·25) and in those with HER2-positive, hormone-receptor-
negative tumours who received trastuzumab (EFS: 0·15, 0·09–0·27; OS: 0·08, 0·03, 0·22). In the trial-level analysis, we 
recorded little association between increases in frequency of pathological complete response and EFS (R²=0·03, 95% CI 
0·00–0·25) and OS (R²=0·24, 0·00–0·70).
Interpretation Patients who attain pathological complete response deﬁ ned as ypT0 ypN0 or ypT0/is ypN0 have 
improved survival. The prognostic value is greatest in aggressive tumour subtypes. Our pooled analysis could not 
validate pathological complete response as a surrogate endpoint for improved EFS and OS.
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Introduction
New agents to treat breast cancer have historically been 
approved ﬁ rst in the metastatic setting, with approval for 
use in early-stage breast cancer following many years 
later on the basis of results of large randomised adjuvant 
trials with long follow-up. Neoadjuvant treatment—
systemic therapy delivered before deﬁ nitive breast cancer 
surgery—was once reserved to reduce the size and extent 
of locally advanced tumours, but is now being used more 
widely. In addition to increasing the likelihood of tumour 
control and the potential for curability in early breast 
cancer, neoadjuvant trials allow rapid assessment of drug 
eﬃ  cacy and could expedite development and approval of 
treat ments for early breast cancer.1 Pathological complete 
response has been proposed as a surrogate endpoint for 
prediction of long-term clinical beneﬁ t, such as disease-
free survival and overall survival (OS).2–5
Although pathological complete response has been the 
most commonly used endpoint in neoadjuvant trials, it 
has been variably deﬁ ned, which has made reporting and 
interpretation of data challenging. One way to optimise 
the deﬁ nition of pathological complete response, enable 
the interpretation of data, and investigate the association 
between pathological complete response and long-term 
outcome is via a pooled analysis of neoadjuvant trials. To 
obtain the requisite number of trials for this pooled 
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analysis, the US Food and Drug Administration estab-
lished an international working group known as Collab-
or ative Trials in Neoadjuvant Breast Cancer (CTNeoBC) 
with investigators who had done neoadjuvant trials for 
which long-term data are available.
We aimed to investigate the potential of pathological 
complete response as a surrogate endpoint for long-term 
outcomes. We had four key objectives: to establish the 
association between pathological complete response and 
event-free survival (EFS) and OS, to establish the deﬁ nition 
of pathological complete response that corre lates best with 
long-term outcome, to identify the breast cancer subtypes 
in which pathological complete response is best correlated 
with long-term outcome, and to assess whether an increase 
in frequency of patho logical complete response predicts 
improved EFS and OS. Here, we present initial results 
from the CTNeoBC pooled analysis.
Methods
Search strategy and selection criteria
We searched PubMed, Embase, and Medline for reports 
of clinical trials of neoadjuvant treatment of breast cancer 
published between Jan 1, 1990, and Aug 1, 2011. To be 
eligible, studies had to meet three inclusion criteria: 
include at least 200 patients with primary breast cancer 
treated with preoperative chemo therapy followed by 
surgery; have available data for pathological complete 
response, EFS, and OS; and have a median follow-up of 
at least 3 years.
Investigators from identiﬁ ed trials were invited to 
participate in a collaborative analysis and agreed to 
provide individual patient data. We excluded data from 
all patients randomised to postoperative treatment, 
patients in the HER2-negative treatment group of the 
NOAH trial (necessary data were unavailable for this 
group), and patients who never began assigned 
treatment.
Outcome measures
Deﬁ nitions of pathological complete response varied 
across trials. We compared the three most commonly 
used pathological complete response deﬁ nitions to 
establish their association with long-term outcome: 
ypT0 ypN0 (ie, absence of invasive cancer and in-situ 
cancer in the breast and axillary nodes), ypT0/is ypN0 
(ie, absence of invasive cancer in the breast and axillary 
nodes, irrespective of ductal carcinoma in situ), and 
ypT0/is (ie, absence of invasive cancer in the breast irres-
pective of ductal carcinoma in situ or nodal involve ment). 
All trials had standard operating pro cedures for patho-
logical com plete response assessments.
The endpoint of choice for adjuvant trials has been 
disease-free survival, reﬂ ecting the fact that patients are 
disease free at the time of randomisation. By contrast, 
EFS is used in neoadjuvant trials because all patients are 
not disease free at randomisation. We calculated EFS as 
the inter val from randomisation to the earliest 
occurrence of disease progression resulting in 
inoperability, loco regional recur rence (after neoadjuvant 
therapy), distant meta stases, or death from any cause. 
Patients alive with out an event as of the analysis cutoﬀ  
date were censored at last study follow-up date. Overall 
survival was calcu lated from date of randomisation to 
death. For patients alive on the data cutoﬀ  date, survival 
was censored at last study follow-up date.
Statistical analysis
In the pooled analysis, we categorised patients who either 
did not undergo surgery or who had surgery but for whom 
data were missing for pathological complete response as 
non-pathological complete responders. We compared the 
three deﬁ nitions of pathological com plete response for 
their association with EFS and OS. In this responder 
analysis, EFS and OS were com pared between patients 
with and without pathological complete response, 
irrespective of treatment assign ment, with a log-rank test 
stratiﬁ ed by study. We esti mated hazard ratios (HRs) and 
95% CIs of EFS and OS from stratiﬁ ed Cox regression 
models with study as a stratiﬁ cation factor. We also 
obtained Kaplan-Meier estimates of EFS and OS by 
pathological complete response status. We assessed the 
association between pathological complete response and 
EFS and OS in various subgroups. We did multivariable 
analyses with Cox regression models including baseline 
factors (age, tumour stage, nodal status, histological type, 
tumour grade, and tumour subtype) and pathological 
complete response status. We excluded patients with 
missing factors from the multivariable analyses.
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Figure 1: Study proﬁ le
13 856 patients enrolled in 12 neoadjuvant trials
11 955 included in responder analysis
2515 excluded 
 1713 in non-randomised neoadjuvant
  groups (451 from ECTO; 285 from 
  GeparTrio–Pilot; 760 from NSABP 
  B-18; 217 from TECHNO)
 802 given additional adjuvant taxane
  in NSABP B-27
9440 included in the trial-level analysis
1901 excluded 
 1667 assigned to adjuvant treatment (904 
  from ECTO; 763 from NSABP B-18)
 99 in the HER2-negative treatment 
  group of the NOAH trial
 1 in the HER2-positive treatment 
  group of the NOAH trial for whom no 
  data obtained
 134 never began assigned treatment 
  (60 from GeparTrio; 74 from 
  GeparQuattro)
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To explore the potential of pathological complete 
response as a surrogate endpoint for EFS or OS in a 
trial-level analysis, we quantiﬁ ed the association between 
treatment eﬀ ects on pathological complete response and 
EFS and OS using a weighted linear regression model 
on a logarith mic scale. We excluded data from patients 
in non-randomised groups from this analysis, because 
we could not estimate the treatment eﬀ ect size in these 
groups. We also excluded patients in NSABP B-27 who 
received additional adjuvant taxane treatment because 
the neoadjuvant treatment eﬀ ect could not be isolated.
We present treatment eﬀ ects on EFS and OS as 
HRs (calcu lated with Cox proportional hazards models) 
and on pathological complete response as odds ratios 
(calculated with logistic regression models) within each 
randomised comparison. The linear regression model 
was weighted by sample size of each randomised com-
parison. Using a two-stage model to adjust for the 
estimation error of treatment eﬀ ect size estimates,6 we 
calculated the coeﬃ  cient of determination (R²) and the 
associated 95% CI to measure the correlation between 
pathological complete response and EFS and OS by 
treatment eﬀ ect. By convention, an HR (experimental vs 
control) of less than 1 denotes a favourable result for 
EFS and OS in the experimental group, and an odds 
ratio (experimental vs control) of more than 1 denotes a 
favourable result for pathological complete response. 
Thus, a strong negative correlation between log hazard 
ratio for EFS or OS and log odds ratio for pathological 
complete response would validate pathological complete 
response as a surrogate for long-term clinical beneﬁ t. 
All analyses were done with SAS (version 9.2).
Results
We identiﬁ ed 12 international neoadjuvant trials: AGO 1 
(n=668),7 ECTO (n=1355),8 EORTC 10994/BIG 1-00 
Figure 2: Associations between pathological complete response and event-free survival and overall survival
ypT0/is ypN0 deﬁ nition of pathological complete response (ie, absence of invasive cancer in the breast and axillary nodes, irrespective of ductal carcinoma in situ). 
HR=hazard ratio.
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Figure 3: Associations between three deﬁ nitions of pathological complete response and event-free survival and overall survival
We compared event-free survival and overall survival between patients who did and did not achieve a pathological complete response according to one of three 
deﬁ nitions. Patients who did not achieve a pathological complete response are not shown. Number of patients who achieved a pathological complete response is listed 
for each pathological complete response deﬁ nition. Patients could achieve pathological complete response according to more than one deﬁ nition. ypT0 ypN0=absence 
of invasive cancer and in-situ cancer in the breast and axillary nodes. ypT0/is ypN0=absence of invasive cancer in the breast and axillary nodes, irrespective of ductal 
carcinoma in situ. ypT0/is=absence of invasive cancer in the breast, irrespective of ductal carcinoma in situ or nodal involvement. HR=hazard ratio.
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(n=1856),9 GeparDuo (n=907),10 GeparQuattro (n=1495),11,12 
GeparTrio (n=2072),13,14 GeparTrio-Pilot (n=285),15 NOAH 
(n=334),16 NSABP B-18 (n=1523),17,18 NSABP B-27 (n=2411),18,19 
PREPARE (n=733),20,21 and TECHNO (n=217; appendix).22 
No major trial was excluded from the pooled analysis. All 
were randomised controlled trials except for TECHNO,22 
which was a single-group study previously included in the 
pooled analysis of the German neo adjuvant trials.23
In each trial, heterogeneous populations of patients 
were enrolled and randomised comparisons of 
Figure 4: Percentage of patients achieving pathological complete response (A) and HRs for overall survival (B), by subgroup
Information about clinical tumour stage available for 11 869 patients, about clinical nodal status for 11 807 patients, about histological type for 10 263 patients, 
about tumour grade for 8035 patients, and about clinical tumour subtype for 5694 patients. ypT0/is ypN0 deﬁ nition of pathological complete response used. No 
multiplicity adjustment was made. HR=hazard ratio.
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anthracycline-based and taxane-based regimens were 
done, with the exception of the NOAH16 and TECHNO22 
trials, which were limited to patients with HER2-
positive locally advanced or inﬂ ammatory breast cancer. 
Patients in the NOAH16 trial were randomly assigned to 
preoperative chemotherapy with or without 
trastuzumab, and those in the TECHNO22 trial received 
trastuzumab and chemo therapy followed by 1 year of 
adjuvant trastuzumab. In the GeparQuattro trial,11,12 
patients with HER2-positive tumours received trastu-
zumab con comitantly with chemotherapy. Overall, 1087 
(55%) of 1989 patients with HER2-positive tumours 
included in the pooled analysis did not receive 1 year of 
adjuvant trastuzumab because they were treated before 
adjuvant trastuzumab trials were reported. All 
patients with hormone-receptor-positive tumours were 
supposed to receive at least 5 years of endocrine therapy. 
Breast cancer subtype was established by clinic-
opathological criteria, such as hormone-receptor status, 
HER2 overexpression, and histological grade as 
assessed by local pathologists. The Ki-67 labelling index 
had not been routinely assessed in the included studies.
11 955 patients were included in our pooled responder 
analysis (ﬁ gure 1). Baseline characteristics are shown in 
the appendix. Median age was 49 years (IQR 43–57). 
7328 patients (61%) had T2 tumours, 482 (4%) had 
inﬂ ammatory breast cancer (ie, T4d tumours), and 
5487 (46%) had clinically involved lymph nodes. 
3572 (30%) patients had hormone-receptor-negative 
breast cancer, and 1989 (17%) had HER2-positive 
Figure 5: Association between pCR and event-free survival, by breast cancer subtype
pCR=pathological complete response. HR=hazard ratio.
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tumours. Tumour testing for HER2 was not necessary in 
the earlier trials, so infor mation about HER2-receptor 
status was not available for four trials (AGO-1,7 NSABP 
B-18,17 NSABP B-27,19 and ECTO8). Overall median follow-
up for EFS was 5·40 years (95% CI 5·33–5·44) and for 
OS was 5·37 years (5·31–5·43).
Overall frequency of patho logical complete response 
was low, and the frequency decreased with increasingly 
stringent deﬁ nitions: 22% (95% CI 21–22) of patients 
achieved ypT0/is, 18% (17–19) achieved ypT0/is ypN0, 
and 13% (12–14) achieved ypT0 ypN0. Overall, patients 
who achieved a pathological complete response had 
longer EFS and OS than did patients with residual 
invasive cancer (ﬁ gures 2, 3). Eradication of tumour 
from both the breast and axillary lymph nodes (ypT0 
pN0 and ypT0/is ypN0) was better associated with 
improved EFS and OS than was eradication of invasive 
tumour from the breast alone (ypT0/is; ﬁ gure 3). 
Associations with EFS and OS were similar for ypT0 
ypN0 and ypT0/is ypN0 (ﬁ gure 3). Additionally, 
associations were consistent when we adjusted for 
baseline factors using multivariable Cox models. We 
used the ypT0/is ypN0 deﬁ nition for all subsequent 
analyses.
As expected, frequency of pathological complete 
responses in patients with low-grade, hormone-receptor-
positive tumours was low, and more than doubled in 
the high-grade hormone-receptor-positive subgroup 
(ﬁ gure 4A). The more aggressive subtypes—triple-
negative and HER2-positive tumours—had increased 
frequencies of pathological complete response 
(ﬁ gure 4A). Within the HER2-positive population, patho-
logical com plete response was more common for 
hormone-receptor-negative tumours than for hormone-
receptor-positive tumours, and with the addition of 
trastuzumab (ﬁ gure 4A).
The pathological complete response was positively 
associated with EFS (HR 0·49, 95% CI 0·33–0·71) and 
OS (0·43, 0·23–0·71) in the overall hormone-receptor-
positive, HER2-negative population. The association 
between pathological com plete response and long-term 
outcome was stronger in patients with high-grade 
tumours than in those with low-grade tumours 
(ﬁ gures 4B, 5). Additionally, pathological complete 
response was associated with long-term outcome in the 
HER2-positive subgroup irrespective of hormone-
receptor status (EFS: HR 0·39, 95% CI 0·31–0·50; 
OS: 0·34, 0·24–0·47). The strength of the association 
increased in the hormone-receptor-negative subgroup 
(EFS: 0·25, 0·18–0·34; OS: 0·19, 0·12–0·31). The most 
favourable outcomes after pathological complete response 
were recorded in patients with HER2-positive, hormone-
receptor-negative tumours who received trastuzumab 
(EFS: 0·15, 0·09–0·27; OS: 0·08, 0·03–0·22), and in the 
triple-negative subgroup (ﬁ gures 4B, 5).
We analysed the association between the eﬀ ect of 
treatments on pathological complete response and long-
term outcomes in ten randomised comparisons, excluding 
non-randomised neoadjuvant groups and patients given 
additional adjuvant taxane (ﬁ gure 1). At a trial level, we 
recorded little association between increases in frequency 
of pathological complete response and the treatment’s 
eﬀ ect on EFS or OS (ﬁ gure 6). The coeﬃ  cient of 
determination (R²) between improvement in pathological 
complete response and EFS was 0·03 (95% CI 0·00–0·25), 
and that between improvement in pathological complete 
response and OS was 0·24 (0·00–0·70).
We also investigated the trial-level association between 
pathological complete response and long-term outcome 
by tumour subtype. We excluded patients with low-
grade, hormone-receptor-positive tumours because of 
low frequency of pathological complete response. The 
Figure 6: Trial-level correlation between treatment eﬀ ect on pathological complete response and event-free survival or overall survival
Each circle corresponds to one randomised comparison and the size of the circle represents the sample size. A=GeparQuattro (epirubicin plus cyclophosphamide 
followed by docetaxel then capecitabine vs epirubicin plus cyclophosphamide followed by docetaxel). B=GeparDuo. C=GeparQuattro (epirubicin plus 
cyclophosphamide followed by docetaxel and capecitabine vs epirubicin plus cyclophosphamide followed by docetaxel). D=EORTC 10994/BIG 1-00. E=PREPARE. 
F=NSABP B-27. G=responders in GeparTrio. H=non-responders in GeparTrio. I=AGO 1. J=NOAH.
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results of the analyses by breast cancer subtype were 
consistent with ﬁ ndings in the overall population: no 
correlation between improvement in frequency of 
pathological complete response and the treatment’s 
eﬀ ect on EFS or OS was recorded (appendix).
Discussion
In our pooled analysis, we recorded that eradication of 
tumours from both breast and lymph nodes (ypT0 ypN0 
or ypT0/is ypN0 pathological complete response) had a 
stronger association with improved EFS and OS than did 
eradication of tumour from the breast alone (ypT0/is). 
The strongest association between pathological com-
plete response and long-term outcome was in patients 
with aggressive breast cancer subtypes (triple negative; 
hormone-receptor-positive, high-grade, and HER2-nega-
tive; and HER2-positive and hormone-receptor-negative). 
Nevertheless, an increase in frequency of pathological 
complete response between treatment groups did not 
predict improved EFS and OS.
Standardisation of the deﬁ nition of pathological com-
plete response would allow planning and inter pretation 
of future neoadjuvant clinical trials intended to support 
drug approval. We propose that pathological complete 
response is deﬁ ned as either ypT0/is ypN0 or ypT0 ypN0 
in future trials. However, ypT0 ypN0 is a more stringent 
deﬁ nition and its use could lead to reduced frequencies 
of pathological complete response. Presence or absence 
of ductal carcinoma in situ did not aﬀ ect long-term 
outcome in our analysis. Additionally, a retrospective 
analysis24,25 of a database including more than 
2000 patients treated with neoadjuvant chemotherapy 
showed that residual ductal carcinoma in situ in patients 
with complete eradication of the invasive cancer from the 
breast and lymph nodes did not adversely aﬀ ect survival. 
By contrast, a German pooled analysis26 of seven 
neoadjuvant trials showed that patients without ductal 
carcinoma in situ had longer survival than did patients 
with residual ductal carcinoma in situ when all invasive 
disease was eradicated.
Several other groups have reported improved long-
term outcomes in patients with pathological complete 
response compared with those with residual tumour at 
the time of surgery.17,19,23,24,26 Our pooled analysis 
conﬁ rmed this ﬁ nding in various tumour subtypes and 
in groups divided by other baseline characteristics. The 
strength of the association increased with trastuzumab 
treatment, which emphasises the importance of targeted 
therapy. The association between pathological complete 
response and long-term outcome was weakest for 
hormone-receptor-positive and low-grade tumours, and 
for HER2-positive and hormone-receptor-positive 
tumours. The German pooled analysis23,26 similarly 
showed that the association between pathological 
complete response and long-term outcome was strongest 
in patients with aggressive breast cancer subtypes. 
However, pathological complete response was not 
prognostic in patients with luminal A or luminal B and 
HER2-positive breast cancer.
The diﬀ erence between patient-level analyses and trial-
level analyses is a common source of confusion. Patient-
level analyses, sometimes referred to as responder 
analyses, compare the clinical outcome of patients with 
and without pathological complete response, irrespective 
of the treatment group. These analyses are meaningful 
as they predict improved survival for patients who attain 
pathological complete response. Because these responder 
analyses are independent of the treatment group, they 
are not useful for comparisons of treatments at a trial 
level. The CTNeoBC pooled analysis is the ﬁ rst large 
analysis in which primary source data has been used to 
assess the association between pathological complete 
response and EFS and OS at a trial level.
We propose four potential explanations for the 
ﬁ nding that an increase in frequency of pathological 
complete response between treatment groups did not 
predict improved EFS and OS. First, in most of the 
included trials, women with heterogeneous breast 
cancer tumour subtypes were enrolled, which would be 
expected to obscure the association between path-
ological complete response and survival if subtypes 
respond diﬀ erently to the same treatment, or if diﬀ erent 
absolute improvements in frequency of pathological 
complete response are necessary to meaningfully aﬀ ect 
long-term outcomes. Second, a neoadjuvant therapy 
targeted to a speciﬁ c tumour subtype (trastuzumab) 
was used in only three trials (GeparQuattro,12 NOAH,16 
and TECHNO22), and trastuzu mab used as an adjunct 
to chemotherapy in only the NOAH study. As a result, 
absolute diﬀ erences in the frequency of pathological 
complete response between chemotherapy groups in 
the included trials were generally low (1–11%), but were 
as high as 20% for the NOAH trial, comparing 
trastuzumab plus chemotherapy with chemotherapy 
alone (ypT0/is ypN0: 35% vs 15%; odds ratio 3·04, 
95% CI 1·64–5·82). Similarly, the diﬀ er ence in the 
proportion of patients achieving EFS at 5 years between 
treatment groups in the NOAH study was 13%, 
although postoperative trastuzumab in the experimental 
group could have partly contributed to the treatment 
eﬀ ect. Fourth, factors unrelated to primary tumour 
response could have had a role. In the HER2-positive 
subgroup, we noted that the addition of one trial with 
increased treatment eﬀ ects (NOAH) decreased the 
slope of the curve, suggesting a trial-level correlation 
between frequency of pathological complete response 
and long-term outcome could be identiﬁ ed in future 
trials with more homogeneous populations and 
incorporation of targeted therapies. Future trials of 
subtype-speciﬁ c popu lations with diﬀ er ences in 
frequency of pathological complete response between 
treatment groups that are larger than are those in the 
trials we included could predict improvement in EFS or 
OS in early-stage breast cancer.
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The importance of individual-level association should 
not be overlooked; it oﬀ ers insight into the natural 
history of an individual’s disease and is thus useful to 
counsel patients. Trial-level association is useful to 
predict population treatment beneﬁ ts. As previously 
suggested,6,27 an acceptable surrogate endpoint should be 
correlated with outcome at both the individual and trial 
levels. Our pooled analysis could not establish a trial-
level correlation between pathological complete response 
and long-term outcome. In view of the substantial 
improvements in survival for individual patients who 
attain pathological complete response, we believe that if a 
novel agent produces a marked absolute increase in 
frequency of pathological complete response compared 
with standard therapy alone in the intention-to-treat 
population, that agent could also be reasonably likely to 
result in long-term improvements in EFS or OS.28 In our 
future analyses (with genomic assays to better charac-
terise subgroups and including additional anti-HER2 
trials), we will investigate the importance of pathological 
complete response in deﬁ ned subsets and assess other 
promising surrogate endpoints.
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